Paclitaxel plus valproic acid versus paclitaxel alone as second- or third-line therapy for advanced gastric cancer: a randomized Phase II trial

Figures & data

Table 1 Patient characteristics

Characteristics	PTX (n=33) group	PTX plus VPA (n=33) group
Median age (range), years	68 (49–84)	67 (31–83)
ECOG PS, n (%)
0–1	28 (85)	29 (88)
2	5 (15)	4 (12)
Prior CTX, n (%)
First-line	22 (67)	20 (61)
Second-line	11 (33)	13 (39)
Target lesion, n (%)
Yes	11 (33)	11 (33)
No	22 (67)	22 (67)

Abbreviations: PTX, paclitaxel; VPA, valproic acid; ECOG PS, Eastern Cooperative Oncology Group performance status; CTX, chemotherapy.

Figure 1 Trial profile.

Abbreviations: PTX, paclitaxel; VPA, valproic acid.

Figure 2 Kaplan–Meier curves of overall survival (A) and progression-free survival (B).

Abbreviations: OS, overall survival; PTX, paclitaxel; VPA, valproic acid; PFS, progression-free survival.

Figure 3 Forest plot of subgroup analyses.

Abbreviations: CI, confidence interval; HR, hazard ratio; ECOG PS, Eastern Cooperative Oncology Group performance status; CTX, chemotherapy; wPTX, weekly paclitaxel; VPA, valproic acid.